Nascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0969 USD | +7.67% | -1.62% | -43.96% |
1st Jan change | Capi. | |
---|---|---|
-43.96% | 16.53M | |
+19.33% | 125B | |
+13.95% | 108B | |
-3.53% | 24.57B | |
+3.49% | 22.82B | |
-10.37% | 18.19B | |
-41.48% | 16.54B | |
-12.62% | 16.5B | |
+0.99% | 13.39B | |
+21.79% | 11.1B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer